NCT04175808View on ClinicalTrials.gov

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

March 4, 2020

Study Completion Date

March 4, 2020

Conditions
QT Intervals ChangesQTc Intervals Changes
Interventions
DRUG

Omecamtiv Mecarbil (OM)

Oral solution

DRUG

Placebo

Placebo oral solution

DRUG

Moxifloxacin

400 mg moxifloxacin oral tablet

Trial Locations (1)

LS2 9LH

Research Site, Leeds

Sponsors

Lead Sponsor

Cytokinetics
All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT04175808 - Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults | Biotech Hunter | Biotech Hunter